These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 31086147)

  • 21. A phase II, non-comparative randomised trial of two treatments involving liposomal amphotericin B and miltefosine for post-kala-azar dermal leishmaniasis in India and Bangladesh.
    Sundar S; Pandey K; Mondal D; Madhukar M; Kamal Topno R; Kumar A; Kumar V; Kumar Verma D; Chakravarty J; Chaubey R; Kumari P; Rashid MU; Maruf S; Ghosh P; Raja S; Rode J; den Boer M; Das P; Alvar J; Rijal S; Alves F
    PLoS Negl Trop Dis; 2024 Jun; 18(6):e0012242. PubMed ID: 38900786
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Post-Kala-Azar Dermal Leishmaniasis Without Previous History of Visceral Leishmaniasis.
    Hasnain G; Shomik MS; Ghosh P; Rashid MO; Hossain S; Hamano S; Mondal D
    Am J Trop Med Hyg; 2016 Dec; 95(6):1383-1385. PubMed ID: 27672208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Severe post-kala-azar dermal leishmaniasis successfully treated with miltefosine in an Ethiopian HIV patient.
    Abongomera C; Battaglioli T; Adera C; Ritmeijer K
    Int J Infect Dis; 2019 Apr; 81():221-224. PubMed ID: 30790722
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A case report on para-kala-azar dermal leishmaniasis: an unresolved mystery.
    Hasan MM; Proma SB; Hossain MS; Arifuzzaman M; Islam N; Siddique MAB; Amiruzzaman
    BMC Infect Dis; 2023 Dec; 23(1):885. PubMed ID: 38110894
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.
    Singh RP; Picado A; Alam S; Hasker E; Singh SP; Ostyn B; Chappuis F; Sundar S; Boelaert M
    Trop Med Int Health; 2012 Nov; 17(11):1345-8. PubMed ID: 22882665
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical and immunological aspects of post-kala-azar dermal leishmaniasis in Bangladesh.
    Islam S; Kenah E; Bhuiyan MA; Rahman KM; Goodhew B; Ghalib CM; Zahid MM; Ozaki M; Rahman MW; Haque R; Luby SP; Maguire JH; Martin D; Bern C
    Am J Trop Med Hyg; 2013 Aug; 89(2):345-53. PubMed ID: 23817330
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of leishmaniasis with miltefosine: 2008 status.
    Berman JJ
    Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1209-16. PubMed ID: 18721114
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Successful miltefosine treatment of post-kala-azar dermal leishmaniasis occurring during antiretroviral therapy.
    Belay AD; Asafa Y; Mesure J; Davidson RN
    Ann Trop Med Parasitol; 2006 Apr; 100(3):223-7. PubMed ID: 16630379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A case of miltefosine responsive pleomorphic post kala-azar dermal leishmaniasis.
    Pal D; Naskar A; Ghosh MK
    Braz J Infect Dis; 2013; 17(5):610-2. PubMed ID: 24012431
    [No Abstract]   [Full Text] [Related]  

  • 30. Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis.
    Ramesh V; Katara GK; Verma S; Salotra P
    Br J Dermatol; 2011 Aug; 165(2):411-4. PubMed ID: 21561437
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Post-kala-azar dermal leishmaniasis (PKDL) drug efficacy study landscape: A systematic scoping review of clinical trials and observational studies to assess the feasibility of establishing an individual participant-level data (IPD) platform.
    Singh-Phulgenda S; Kumar R; Dahal P; Munir A; Rashan S; Chhajed R; Naylor C; Maguire BJ; Siddiqui NA; Harriss E; Rahi M; Alves F; Sundar S; Stepniewska K; Musa A; Guerin PJ; Pandey K
    PLoS Negl Trop Dis; 2024 Apr; 18(4):e0011635. PubMed ID: 38626228
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A male preponderance in patients with Indian post kala-azar dermal leishmaniasis is associated with increased circulating levels of testosterone.
    Mukhopadhyay D; Mukherjee S; Ghosh S; Roy S; Saha B; Das NK; Chatterjee M
    Int J Dermatol; 2016 May; 55(5):e250-5. PubMed ID: 26536363
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful treatment of post-kala-azar dermal leishmaniasis (PKDL) in a HIV infected patient with multiple relapsing leishmaniasis from Western Europe.
    Rihl M; Stoll M; Ulbricht K; Bange FC; Schmidt RE
    J Infect; 2006 Jul; 53(1):e25-7. PubMed ID: 16274744
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Keratitis occurring in patients treated with miltefosine for post-kala-azar dermal leishmaniasis.
    Kusumesh R; Ambasta A; Arya LK; Mohan N; Sinha BP; Ravidas V
    Br J Ophthalmol; 2021 Nov; 105(11):1497-1503. PubMed ID: 32962993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral miltefosine in the treatment of post-kala-azar dermal leishmaniasis.
    Ramesh V; Ansari NA; Jain RK; Salotra P
    Clin Exp Dermatol; 2008 Jan; 33(1):103-5. PubMed ID: 17979988
    [No Abstract]   [Full Text] [Related]  

  • 36. Safety and efficacy of paromomycin/miltefosine/liposomal amphotericin B combinations for the treatment of post-kala-azar dermal leishmaniasis in Sudan: A phase II, open label, randomized, parallel arm study.
    Younis BM; Mudawi Musa A; Monnerat S; Abdelrahim Saeed M; Awad Gasim Khalil E; Elbashir Ahmed A; Ahmed Ali M; Noureldin A; Muthoni Ouattara G; Nyakaya GM; Teshome S; Omollo T; Ochieng M; Egondi T; Mmbone M; Chu WY; Dorlo TPC; Zijlstra EE; Wasunna M; Alvar J; Alves F
    PLoS Negl Trop Dis; 2023 Nov; 17(11):e0011780. PubMed ID: 37988402
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine.
    Sundar S; Kumar K; Chakravarty J; Agrawal D; Agrawal S; Chhabra A; Singh V
    Trans R Soc Trop Med Hyg; 2006 Jul; 100(7):698-700. PubMed ID: 16325873
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India.
    Ramesh V; Singh R; Avishek K; Verma A; Deep DK; Verma S; Salotra P
    PLoS Negl Trop Dis; 2015; 9(10):e0004093. PubMed ID: 26492039
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adverse ocular events on miltefosine treatment for post-kala-azar dermal leishmaniasis in India.
    Saurabh S; Mahabir M
    Trop Doct; 2020 Jan; 50(1):37-42. PubMed ID: 31610724
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acute uveitis: A rare adverse effect of miltefosine in the treatment of post-kala-azar dermal leishmaniasis.
    Pandey K; Pal B; Topno RK; Lal CS; Das VNR; Das P
    Rev Soc Bras Med Trop; 2020; 54():e20200208. PubMed ID: 33338118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.